MyDx Cannabis Formula Trial for Pain Management Gets Under Way

A PPM Brief

The biopharmaceutical division of MyDx, Inc. (San Diego, CA) will begin a randomized, controlled trial of its cannabis formula with patients suffering from chronic low back pain. The study will be conducted In Israel and is based on a proprietary formula derived from more than 50,000 “preclinical, crowd-sourced physiological data-points” that tied user experiences to the chemical makeup of a particular strain of cannabis, according to a company release.

Our data gives us amazing insights into how the chemical properties of cannabis impact our base of users,” said Daniel Yazbeck, CEO of MyDx in the release. “Now we're taking those insights into the pharmaceutical arena to confirm our preliminary findings.”

The trial will also examine efficacy on secondary indications such as sleep, depression, and anxiety.